- Tytuł:
- Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
- Autorzy:
- Źródło:
- In The Lancet 15-21 January 2022 399(10321):237-248
Czasopismo naukowe